This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Ocular/ Adnexal Tumors  • Prognosis/ Outcomes  • Genetics  • Genetic Counseling/ Testing/ Therapy  • Alert me on articles by topic  Social Bookmarking   What's this?

Has It Finally Come of Age?

J. William Harbour, MD

Arch Ophthalmol. 2007;125(8):1122-1123.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Uveal melanoma continues to be one of the deadliest diseases encountered in ophthalmology, with many patients dying of metastatic disease. Despite improvements in diagnosis and treatment of the primary tumor, there has not been a corresponding improvement in survival.¹ This inability to prevent metastatic disease appears to be due to clinically undetectable micrometastasis occurring before the primary tumor is treated and becoming clinically manifest only months to years later.² As a result, survival from uveal melanoma is unlikely to improve in the foreseeable future solely through incremental improvements in managing the primary tumor. Concurrently, there are no existing therapies, or new ones on the horizon, with a reasonable prospect of improving survival in patients with advanced metastatic melanoma, so waiting for overt metastatic disease to manifest before initiating systemic therapy will continue to be of limited value. If patients with uveal melanoma are to live longer, . . . [Full Text of this Article]

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Chromosome 3 Analysis of Uveal Melanoma Using Fine-Needle Aspiration Biopsy at the Time of Plaque Radiotherapy in 140 Consecutive Cases: The Deborah Iverson, MD, Lectureship
Carol L. Shields, Arupa Ganguly, Miguel A. Materin, Luiz Teixeira, Arman Mashayekhi, Lori Ann Swanson, Brian P. Marr, and Jerry A. Shields
Arch Ophthalmol. 2007;125(8):1017-1024.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cytogenetics in the Management of Uveal Melanoma: Are We There Yet?
Robertson
Arch Ophthalmol 2008;126:409-410.
FULL TEXT